We periodically analyzed bone-marrow cytogenetic features in 8 patients belonging to a series of 38 subjects with polycythemia vera (PV), all treated with recombinant interferon-alpha 2a (rIFN-alpha) at a weekly dose of 9,000,000 IU. Six out of these 8 patients never showed any chromosome alterations, while 2 displayed at diagnosis the presence of trisomy 8 in all bone-marrow metaphases. interestingly enough, in these 2 patients rIFN-alpha treatment was able to induce not only complete hematological response but also the disappearance of trisomy 8, as shown by conventional cytogenetic investigation and fluorescence in situ hybridization performed on bone-marrow cells after : year of treatment. This finding indicates that, as previously shown in chronic myeloid leukemia, in PV rIFN-alpha can also eradicate the malignant clone by means of a selective effect on hone-marrow transformed cells. (C) 1997 Wiley-Liss, Inc.

Polycythemia vera treated with recombinant interferon-alpha 2a: Evidence of a selective effect on the malignant clone / P. Massaro, P. Foa, M. Pomati, M. LaTargia, A. Iurlo, C. Clerici, S. Caldiera, M. Fornier, A. Maiolo. - In: AMERICAN JOURNAL OF HEMATOLOGY. - ISSN 0361-8609. - 56:2(1997), pp. 126-128. [10.1002/(SICI)1096-8652(199710)56:2<126::AID-AJH10>3.0.CO;2-A]

Polycythemia vera treated with recombinant interferon-alpha 2a: Evidence of a selective effect on the malignant clone

P. Foa;
1997

Abstract

We periodically analyzed bone-marrow cytogenetic features in 8 patients belonging to a series of 38 subjects with polycythemia vera (PV), all treated with recombinant interferon-alpha 2a (rIFN-alpha) at a weekly dose of 9,000,000 IU. Six out of these 8 patients never showed any chromosome alterations, while 2 displayed at diagnosis the presence of trisomy 8 in all bone-marrow metaphases. interestingly enough, in these 2 patients rIFN-alpha treatment was able to induce not only complete hematological response but also the disappearance of trisomy 8, as shown by conventional cytogenetic investigation and fluorescence in situ hybridization performed on bone-marrow cells after : year of treatment. This finding indicates that, as previously shown in chronic myeloid leukemia, in PV rIFN-alpha can also eradicate the malignant clone by means of a selective effect on hone-marrow transformed cells. (C) 1997 Wiley-Liss, Inc.
Settore MED/06 - Oncologia Medica
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/187329
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 35
  • ???jsp.display-item.citation.isi??? 37
social impact